Document is current

Article History

Accepted: 6 June 2023

First Online: 26 June 2023

Declarations

:

: The studies were funded by Bayer AG. Medical writing and editorial assistance were provided by Oxford PharmaGenesis, Oxford, UK, funded by Bayer AG.

: IP, DL, SS, CB, WJ, LF, SH, and FK are employees of Bayer AG and own shares or share options. AE and MG were employees of Bayer AG at the time of conducting the study and data analysis.

: The data that support the findings of this study are available from the corresponding author, FK, upon reasonable request.

: The conduct of this clinical study met all local legal and regulatory requirements. The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and the International Council for Harmonisation guideline E6, Good Clinical Practice, and in accordance with Dutch drug law. The protocol was reviewed and approved by the study site’s Independent Ethics Committee (IEC, Stichting Beoordeling Ethiek Biomedisch Onderzoek, Assen, Netherlands).

: A signed informed consent form was provided by each participant after being allowed ample time to read the form and ask questions about the procedures.

: Not applicable.

: Not applicable.

: <i>Participated in research design:</i> Dieter Lang, Friederike Kanefendt, Isabel Piel, Lukas Fiebig, Michael Gerisch, Simone I. Schulz. <i>Conducted experiments:</i> Anna Engelen, Dieter Lang, Isabel Piel, Simone I. Schulz, Stefan Heitmeier, Wiebke Janssen. <i>Performed data analysis:</i> Anna Engelen, Christine Brase, Dieter Lang, Friederike Kanefendt, Isabel Piel, Lukas Fiebig, Michael Gerisch, Simone I. Schulz, Stefan Heitmeier. <i>Wrote or contributed to the writing of the manuscript:</i> Anna Engelen, Christine Brase, Dieter Lang, Friederike Kanefendt, Isabel Piel, Lukas Fiebig, Michael Gerisch, Simone I. Schulz, Stefan Heitmeier, Wiebke Janssen.